{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T05:43:36Z","timestamp":1648705416917},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,10,2]],"date-time":"2009-10-02T00:00:00Z","timestamp":1254441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00120-009-2105-2","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T12:58:16Z","timestamp":1254315496000},"page":"1263-1272","source":"Crossref","is-referenced-by-count":0,"title":["Intravesikale Therapie beim nicht muskelinvasiven Urothelkarzinom der Harnblase"],"prefix":"10.1007","volume":"48","author":[{"given":"J.","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Finter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schn\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hautmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rinnab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,2]]},"reference":[{"key":"2105_CR1","first-page":"26","volume":"26","author":"van","year":"2009","unstructured":"van Rhijn BW, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 26:26","journal-title":"Eur Urol"},{"key":"2105_CR2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2008.04.016","volume":"180","author":"Huang","year":"2008","unstructured":"Huang GJ, Hamilton AS, Lo M et al (2008) Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol 180:520\u2013524","journal-title":"J Urol"},{"key":"2105_CR3","first-page":"31","volume":"31","author":"May","year":"2009","unstructured":"May M, Brookman-Amissah S, Roigas J et al (2009) Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 world health organisation classifications. Eur Urol 31:31","journal-title":"Eur Urol"},{"key":"2105_CR4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","volume":"54","author":"Babjuk","year":"2008","unstructured":"Babjuk M, Oosterlinck W, Sylvester R et al (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303\u2013314","journal-title":"Eur Urol"},{"key":"2105_CR5","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"Hall","year":"2007","unstructured":"Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314\u20132330","journal-title":"J Urol"},{"key":"2105_CR6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eursup.2008.07.009","volume":"7","author":"Lamm","year":"2008","unstructured":"Lamm DL, Colombel M, Persad R et al (2008) Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol 7(Suppl):651\u2013666","journal-title":"Eur Urol"},{"key":"2105_CR7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013467","journal-title":"Eur Urol"},{"key":"2105_CR8","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","volume":"171","author":"Sylvester","year":"2004","unstructured":"Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186\u20132190","journal-title":"J Urol"},{"key":"2105_CR9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","volume":"55","author":"Gudjonsson","year":"2009","unstructured":"Gudjonsson S, Adell L, Merdasa F et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55:773\u2013780","journal-title":"Eur Urol"},{"key":"2105_CR10","first-page":"458","volume":"Urol","author":"Holmang","year":"2009","unstructured":"Holmang S (2009) Early single-instillation chemotherapy has no real benefit and should be abandoned in non-muscle-invasive bladder cancer. Eur Urol (Suppl 8):458\u2013463","journal-title":"Eur"},{"key":"2105_CR11","doi-asserted-by":"crossref","unstructured":"Berrum-Svennung I, Granfors T, Jahnson S et al (2008) A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol. 179:101\u2013106","DOI":"10.1016\/j.juro.2007.08.166"},{"key":"2105_CR12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1464-410X.2009.08654.x","volume":"104","author":"Dobruch","year":"2009","unstructured":"Dobruch J, Herr H (2009) Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int 104:170\u2013174","journal-title":"BJU Int"},{"key":"2105_CR13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cncr.24104","volume":"115","author":"Rao","year":"2009","unstructured":"Rao PK, Stephen Jones J (2009) Routine perioperative chemotherapy instillation with initial bladder tumor resection: a reconsideration of economic benefits. Cancer 115:997\u20131004","journal-title":"Cancer"},{"key":"2105_CR14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eursup.2009.01.001","volume":"8","author":"Solsona","year":"2009","unstructured":"Solsona E (2009) Early single instillation chemotherapy is very beneficial and should be the standard approach in non-muscle-invasive bladder cancer. Eur Urol 8(Suppl):464\u2013469","journal-title":"Eur Urol"},{"key":"2105_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.juro.2008.03.038","volume":"180","author":"Cai","year":"2008","unstructured":"Cai T, Nesi G, Tinacci G et al (2008) Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 180:110\u2013115","journal-title":"J Urol"},{"key":"2105_CR16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","volume":"93","author":"Shelley","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J et al (2004) Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93:485\u2013490","journal-title":"BJU Int"},{"key":"2105_CR17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"Bohle","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395","journal-title":"J Urol"},{"key":"2105_CR18","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"Sylvester","year":"2002","unstructured":"Sylvester RJ, van der MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964\u20131970","journal-title":"J Urol"},{"key":"2105_CR19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"Bohle","year":"2004","unstructured":"Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63:682\u2013687","journal-title":"Urology"},{"key":"2105_CR20","first-page":"402","volume":"26","author":"Huncharek","year":"2003","unstructured":"Huncharek M, Kupelnick B (2003) Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol 26:402\u2013407","journal-title":"Am J Clin Oncol"},{"key":"2105_CR21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.eururo.2008.06.062","volume":"54","author":"Herr","year":"2008","unstructured":"Herr HW (2008) Is maintenance Bacillus Calmette-Guerin really necessary? Eur Urol 54:971\u2013973","journal-title":"Eur Urol"},{"key":"2105_CR22","first-page":"24","volume":"24","author":"Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin c versus bacillus calmette-guerin for non-muscle-invasive bladder cancer. Eur Urol 24:24","journal-title":"Eur Urol"},{"key":"2105_CR23","first-page":"16","volume":"16","author":"Jarvinen","year":"2009","unstructured":"Jarvinen R, Kaasinen E, Sankila A, Rintala E (2009) Long-term efficacy of maintenance bacillus calmette-guerin versus maintenance mitomycin c instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised finnbladder i study with a 20-year follow-up. Eur Urol 16:16","journal-title":"Eur Urol"},{"key":"2105_CR24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"Friedrich","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H et al (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52:1123\u20131129","journal-title":"Eur Urol"},{"key":"2105_CR25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","volume":"99","author":"Gardmark","year":"2007","unstructured":"Gardmark T, Jahnson S, Wahlquist R et al (2007) Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 99:817\u2013820","journal-title":"BJU Int"},{"key":"2105_CR26","first-page":"3","volume":"3","author":"Sylvester","year":"2009","unstructured":"Sylvester RJ (2009) Bacillus calmette-guerin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. Eur Urol 3:3","journal-title":"Eur Urol"},{"key":"2105_CR27","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.eururo.2007.05.010","volume":"52","author":"Witjes","year":"2007","unstructured":"Witjes JA (2007) What is the optimal BCG dose in non-muscle-invasive bladder cancer? Eur Urol 52:1300\u20131302","journal-title":"Eur Urol"},{"key":"2105_CR28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"2105_CR29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","volume":"53","author":"Sylvester","year":"2008","unstructured":"Sylvester RJ, Oosterlinck W, Witjes JA (2008) The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 53:709\u2013719","journal-title":"Eur Urol"},{"key":"2105_CR30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","volume":"53","author":"Hendricksen","year":"2008","unstructured":"Hendricksen K, Witjes WP, Idema JG et al (2008) Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53:984\u2013991","journal-title":"Eur Urol"},{"key":"2105_CR31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","volume":"7","author":"Witjes","year":"2008","unstructured":"Witjes JA, Palou J, Soloway M (2008) Clinical practical recommendations for the prevention and management of intravesical therapy \u2013 associated adverse events. Eur Urol 7(Suppl):667\u2013674","journal-title":"Eur Urol"},{"key":"2105_CR32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00005392-199707000-00018","volume":"158","author":"Ali-el-Dein","year":"1997","unstructured":"Ali-el-Dein B, el-Baz M, Aly AN et al (1997) Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 158:68\u201373","journal-title":"J Urol"},{"key":"2105_CR33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0090-4295(87)90300-1","volume":"30","author":"Baker","year":"1987","unstructured":"Baker WC, Russo MA, deVere White RW (1987) Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer. Urology 30:357\u2013358","journal-title":"Urology"},{"key":"2105_CR34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1046\/j.1464-410x.2000.00869.x","volume":"86","author":"Cliff","year":"2000","unstructured":"Cliff AM, Heatherwick B, Scoble J, Parr NJ (2000) The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration. BJU Int 86:644\u2013647","journal-title":"BJU Int"},{"key":"2105_CR35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","volume":"93","author":"Au","year":"2001","unstructured":"Au JL, Badalament RA, Wientjes MG et al (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597\u2013604","journal-title":"J Natl Cancer Inst"},{"key":"2105_CR36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.juro.2007.09.031","volume":"179","author":"Naito","year":"2008","unstructured":"Naito S, Koga H, Yamaguchi A et al (2008) Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J Urol 179:485\u2013490","journal-title":"J Urol"},{"key":"2105_CR37","first-page":"4912","volume":"59","author":"Di","year":"1999","unstructured":"Di Stasi SM, Giannantoni A, Massoud R et al (1999) Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 59:4912\u20134918","journal-title":"Cancer Res"},{"key":"2105_CR38","first-page":"875","volume":"57","author":"Di","year":"1997","unstructured":"Di Stasi SM, Vespasiani G, Giannantoni A et al (1997) Electromotive delivery of mitomycin C into human bladder wall. Cancer Res 57:875\u2013880","journal-title":"Cancer Res"},{"key":"2105_CR39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"Di","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170:777\u2013782","journal-title":"J Urol"},{"key":"2105_CR40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"Di","year":"2006","unstructured":"Di Stasi SM, Giannantoni A, Giurioli A et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7:43\u201351","journal-title":"Lancet Oncol"},{"key":"2105_CR41","first-page":"1707","volume":"179","author":"Di","year":"2008","unstructured":"Di Stasi SM, Storti L, Giurioli A et al (2008) Singel immediate preoperative instillation of electromotive Mitomycin-C plus transurethral resection versus transurethral resection alone versus transurethral resection pus immediate Mitomycin-C for pTa bladder tumors: long term results of a prospective randomized trail. J Urol 179:1707","journal-title":"J Urol"},{"key":"2105_CR42","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","volume":"21","author":"Colombo","year":"2003","unstructured":"Colombo R, Da Pozzo LF, Salonia A et al (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21:4270\u20134276","journal-title":"J Clin Oncol"},{"key":"2105_CR43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","volume":"46","author":"van","year":"2004","unstructured":"van der Heijden AG, Kiemeney LA, Gofrit ON et al (2004) Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46:65\u201371","journal-title":"Eur Urol"},{"key":"2105_CR44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","volume":"27","author":"Alfred","year":"2009","unstructured":"Alfred Witjes J, Hendricksen K, Gofrit O et al (2009) Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 27:319\u2013324","journal-title":"World J Urol"},{"key":"2105_CR45","first-page":"21","volume":"21","author":"Halachmi","year":"2009","unstructured":"Halachmi S, Moskovitz B, Maffezzini M et al (2009) Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 21:21","journal-title":"Urol Oncol"},{"key":"2105_CR46","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.juro.2006.03.066","volume":"176","author":"Yossepowitch","year":"2006","unstructured":"Yossepowitch O, Eggener SE, Bochner BH et al (2006) Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 176:482\u2013485","journal-title":"J Urol"},{"key":"2105_CR47","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/01.TP.0000090748.32764.0F","volume":"76","author":"Palou","year":"2003","unstructured":"Palou J, Angerri O, Segarra J et al (2003) Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 76:1514\u20131516","journal-title":"Transplantation"},{"key":"2105_CR48","first-page":"401","volume":"40","author":"Bohle","year":"2001","unstructured":"Bohle A, Durek C (2001) Use of BCG in superficial urinary bladder carcinoma. Urologe A 40:401\u2013409","journal-title":"Urologe A"},{"key":"2105_CR49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A et al (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147:596\u2013600","journal-title":"J Urol"},{"key":"2105_CR50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"van","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W et al (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44:429\u2013434","journal-title":"Eur Urol"},{"key":"2105_CR51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","volume":"66","author":"Sylvester","year":"2005","unstructured":"Sylvester RJ, van der Meijden A, Witjes JA et al (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66:90\u2013107","journal-title":"Urology"},{"key":"2105_CR52","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","volume":"156","author":"Krege","year":"1996","unstructured":"Krege S, Giani G, Meyer R et al (1996) A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J Urol 156:962\u2013966","journal-title":"J Urol"},{"key":"2105_CR53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-005-0059-2","volume":"26","author":"Tinazzi","year":"2006","unstructured":"Tinazzi E, Ficarra V, Simeoni S et al (2006) Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 26:481\u2013488","journal-title":"Rheumatol Int"},{"key":"2105_CR54","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"Colombel","year":"2006","unstructured":"Colombel M, Saint F, Chopin D et al (2006) The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176:935\u2013939","journal-title":"J Urol"},{"key":"2105_CR55","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van","year":"2001","unstructured":"van der Meijden AP, Brausi M, Zambon V et al (2001) Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166:476\u2013481","journal-title":"J Urol"},{"key":"2105_CR56","first-page":"26","volume":"37","author":"Al","year":"2000","unstructured":"Al Khalifa M, Elfving P, Mansson W et al (2000) The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. Eur Urol 37:26\u201330","journal-title":"Eur Urol"},{"key":"2105_CR57","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","volume":"57","author":"Saint","year":"2001","unstructured":"Saint F, Irani J, Patard JJ et al (2001) Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 57:883\u2013888","journal-title":"Urology"},{"key":"2105_CR58","first-page":"6","volume":"6","author":"Damiano","year":"2009","unstructured":"Damiano R, De Sio M, Quarto G et al (2009) Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity? BJU Int 6:6","journal-title":"BJU Int"},{"key":"2105_CR59","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-410X.2008.08123.x","volume":"103","author":"Gee","year":"2009","unstructured":"Gee JR, Jarrard DF, Bruskewitz RC et al (2009) Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guerin. BJU Int 103:736\u2013739","journal-title":"BJU Int"},{"key":"2105_CR60","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"Martinez-Pineiro","year":"2002","unstructured":"Martinez-Pineiro JA, Flores N, Isorna S et al (2002) Long-term follow-up of a randomized prospective trial comparing a standard 81\u00a0mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27\u00a0mg in superficial bladder cancer. BJU Int 89:671\u2013680","journal-title":"BJU Int"},{"key":"2105_CR61","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"Martinez-Pineiro","year":"2005","unstructured":"Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al (2005) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174:1242\u20131247","journal-title":"J Urol"},{"key":"2105_CR62","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.urology.2007.11.080","volume":"71","author":"Yoneyama","year":"2008","unstructured":"Yoneyama T, Ohyama C, Imai A et al (2008) Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study. Urology 71:1161\u20131165","journal-title":"Urology"},{"key":"2105_CR63","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","volume":"70","author":"Agrawal","year":"2007","unstructured":"Agrawal MS, Agrawal M, Bansal S et al (2007) The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma. Urology 70:1075\u20131078","journal-title":"Urology"},{"key":"2105_CR64","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","unstructured":"Ojea A, Nogueira JL, Solsona E et al (2007) A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27\u00a0mg) versus very low-dose bacillus Calmette-Guerin (13.5\u00a0mg) versus mitomycin C. Eur Urol 52:1398\u20131406","journal-title":"Eur Urol"},{"key":"2105_CR65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","volume":"37","author":"Bassi","year":"2000","unstructured":"Bassi P, Spinadin R, Carando R et al (2000) Modified induction course: a solution to side-effects? Eur Urol 37:31\u201332","journal-title":"Eur Urol"},{"key":"2105_CR66","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","volume":"96","author":"Andius","year":"2005","unstructured":"Andius P, Fehrling M, Holmang S (2005) Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96:1290\u20131293","journal-title":"BJU Int"},{"key":"2105_CR67","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11864-002-0005-4","volume":"3","author":"Lamm","year":"2002","unstructured":"Lamm DL (2002) Superficial bladder cancer. Curr Treat Options Oncol 3:403\u2013411","journal-title":"Curr Treat Options Oncol"},{"key":"2105_CR68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","volume":"45","author":"Witjes","year":"2004","unstructured":"Witjes JA, van der Heijden AG, Vriesema JL et al (2004) Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 45:182\u2013186","journal-title":"Eur Urol"},{"key":"2105_CR69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","volume":"46","author":"Gontero","year":"2004","unstructured":"Gontero P, Casetta G, Maso G et al (2004) Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46:339\u2013343","journal-title":"Eur Urol"},{"key":"2105_CR70","first-page":"21","volume":"21","author":"Bohle","year":"2009","unstructured":"Bohle A, Leyh H, Frei C et al (2009) Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase iii multicentre study. Eur Urol 21:21","journal-title":"Eur Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-009-2105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-009-2105-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-009-2105-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:48:07Z","timestamp":1558612087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-009-2105-2"}},"subtitle":["Indikation und praktisches Management"],"short-title":[],"issued":{"date-parts":[[2009,10,2]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1007\/s00120-009-2105-2","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,2]]}}}